



Restriction Map of pEYFP-Mem. Unique restriction sites are in bold. The *Xba* I site (*) is methylated in the DNA provided by CLONTECH. If you wish to digest this vector with this enzyme, you will need to transform the vector into a *dam*⁻ host and make fresh DNA.

Description:

pEYFP-Mem encodes a fusion protein consisting of the N-terminal 20 amino acids of neuromodulin, also called GAP-43 (1), and a yellow-green fluorescent variant of the enhanced green fluorescent protein (EGFP). The neuromodulin fragment contains a signal for posttranslational palmitoylation of cysteines 3 and 4 that targets EYFP to membranes. The EYFP gene contains four amino acid substitutions previously published as GFP-10C (2). The fluorescence excitation maximum of EYFP is 513 nm, and the emission maximum is 527 nm (in the yellow-green region).

In addition to the chromophore mutations, EYFP contains >190 silent mutations that create an open reading frame comprised almost entirely of preferred human codons (3). Furthermore, upstream sequences flanking the EYFP-Mem fusion protein have been converted to a Kozak consensus translation initiation site (4). These changes increase the translational efficiency of the fusion protein and consequently its expression in mammalian cells.

Expression of EYFP-Mem is driven by the immediate early promoter of CMV (P_{CMVIE}). The vector contains an SV40 origin of replication and a neomycin resistance (*Neo*^r) gene for selection in mammalian cells. A bacterial promoter upstream of this cassette (*P*) expresses kanamycin resistance in *E. coli*. The vector backbone also provides a pUC19 origin of replication for propagation in *E. coli* and an f1 origin for single-stranded DNA production.

Use:

pEYFP-Mem can be transfected into mammalian cells using any standard method. If required, stable transformants can be selected using G418 (5). Expression of EYFP-Mem in mammalian cells results in strong labeling of the plasma membrane and allows easy tracking of individual cells in a population. This membrane labeling also permits study of fine cellular processes such as neuronal axons (6), leading edges of migrating cells, filopodia, or microvilli on cell surfaces. pEYFP-Mem cannot be used as an exclusive plasma membrane marker because it also partially labels intracellular membranes.

Location of features:

- Human cytomegalovirus (CMV) immediate early promoter: 1–589
 - Enhancer region: 59–465
 - TATA box: 554–560
 - Transcription start point: 583
 - C→G mutation to remove *Sac* I site: 569
- EYFP-Mem fusion gene
 - Kozak consensus translation initiation site: 672–682
 - Start codon (ATG): 679–681
 - Neuromodulin N-terminal sequence: 679–738
 - Enhanced yellow fluorescent protein (EYFP) gene: 739–1458
 - Insertion of Val at position 2: 742–744
 - GFP-10C mutations:
 - Ser-65 to Gly: 934–936
 - Val-68 to Leu: 943–945
 - Ser-72 to Ala: 955–957
 - Thr-203 to Tyr: 1348–1350
 - His-231 to Leu mutation (A→T): 1433
 - Stop codon: 1456–1458
- SV40 early mRNA polyadenylation signal
 - Polyadenylation signals: 1612–1617 & 1641–1646
 - mRNA 3' ends: 1650 & 1662
- f1 single-strand DNA origin: 1709–2164
(Packages the noncoding strand of EYFP-Mem.)
- Bacterial promoter for expression of Kan^r gene:
 - 35 region: 2226–2231; –10 region: 2249–2254
 - Transcription start point: 2261
- SV40 origin of replication: 2505–2640
- SV40 early promoter
 - Enhancer (72-bp tandem repeats): 2338–2409 & 2410–2481
 - 21-bp repeats: 2485–2505, 2506–2526 & 2528–2548
 - Early promoter element: 2561–2567
 - Major transcription start points: 2557, 2595, 2601 & 2606
- Kanamycin/neomycin resistance gene
 - Neomycin phosphotransferase coding sequences:
 - Start codon (ATG): 2689–2691; stop codon: 3481–3483
 - G→A mutation to remove *Pst* I site: 2871
 - C→A (Arg to Ser) mutation to remove *Bss*H II site: 3217
- Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
 - Polyadenylation signals: 3719–3724 & 3732–3737
- pUC plasmid replication origin: 4068–4711

Propagation in *E. coli*:

- Suitable host strains: DH5 α , HB101, and other general-purpose strains. Single-stranded DNA production requires a host containing an F plasmid such as JM101 or XL1-Blue.
- Selectable marker: plasmid confers resistance to kanamycin (50 μ g/ml) in *E. coli* hosts.
- *E. coli* replication origin: pUC
- Copy number: ~500
- Plasmid incompatibility group: pMB1/ColE1

References:

1. Skene, J. H. P. & Virag, I. (1989) *J. Cell. Biol.* **108**:613–625.
2. Orm \ddot{o} , M. *et al.* (1996) *Science* **273**:1392–1395.
3. Haas, J., *et al.* (1996) *Curr. Biol.* **6**:315–324.
4. Kozak, M. (1987) *Nucleic Acids Res.* **15**:8125–8148.
5. Gorman, C. (1985) In *DNA cloning: a practical approach, vol. II*. Ed. D. M. Glover. (IRL Press, Oxford, U.K.), pp. 143–190.
6. Moriyoshi, K., *et al.* (1996) *Neuron* **16**:255–260.

Notice to Purchaser

Use of CLONTECH's Living Colors® products containing DNA sequences coding for mutant *Aequorea victoria* green fluorescent protein (GFP) variants or proteins thereof requires a license from Aurora Biosciences Corporation under U.S. Patent Nos. 5,625,048; 5,777,079; 6,054,321 and other pending U.S. and foreign patent applications. In addition, certain CLONTECH products are made under U.S. Patent No. 5,804,387 licensed from Stanford University.

Not-For-Profit research institutes or entities are granted an automatic license with the purchase of this product for use in non-commercial internal research purposes, the terms of which are disclosed in detail in the license that accompanies the shipment of this product. Such license specifically excludes the right to sell or otherwise transfer this product or its components to third parties.

For-Profit research institutes or entities that wish to use this product in non-commercial or commercial applications are required to obtain a license from Aurora Biosciences Corporation. For license information contact: Court Turner at 858-404-8416 or Fax 858-404-6743 or www.aurorabio.com. Please contact CLONTECH directly for any other assistance, including purchasing and technical support.

All companies and institutions purchasing Living Colors® products will be included in a quarterly report to Aurora Biosciences Corporation, as required by the CLONTECH/Aurora license agreement.

The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by CLONTECH. This vector has not been completely sequenced.

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. CLONTECH products may not be resold, modified for resale, or used to manufacture commercial products without written approval of CLONTECH.

© 2000, CLONTECH Laboratories, Inc.